『The Digital Health Podcast with Fexingo: Wearables, Diagnostics, and Health Software』のカバーアート

The Digital Health Podcast with Fexingo: Wearables, Diagnostics, and Health Software

The Digital Health Podcast with Fexingo: Wearables, Diagnostics, and Health Software

著者: Fexingo
無料で聴く

Lucas and Luna explore the rapidly evolving world of digital health, where wearables track vitals, diagnostics shift to at-home testing, and software platforms reshape patient care. Each episode focuses on a specific development: how continuous glucose monitors are changing diabetes management, the FDA's latest clearance for an AI-driven ECG algorithm, or the business models behind telehealth startups like Ro and Hims & Hers. Lucas brings a journalist's precision to the numbers — market sizes, clinical trial results, reimbursement rates — while Luna challenges him on the real-world impact for clinicians and patients. They dissect earnings reports from Apple and Fitbit, parse policy moves from the FDA and CMS, and debate whether VC-funded digital health unicorns can sustain their valuations. Listeners — healthcare professionals, investors, tech strategists — get a clear-eyed briefing on what works, what's hype, and what's next in a sector where staying informed means understanding both the science and the business. How do you separate signal from noise when every startup claims to democratize healthcare? #DigitalHealth #Wearables #HealthTech #Telemedicine #FDA #RemotePatientMonitoring #HealthData #ClinicalTrials #StartupFunding #AppleWatch #Fitbit #ContinuousGlucoseMonitor #AIinHealthcare #VirtualCare #HealthcarePolicy #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo© 2026 Fexingo. All rights reserved. 経済学
エピソード
  • How Wearable Skin Patches Are Replacing Needles for Drug Delivery
    2026/06/07
    In this episode of The Digital Health Podcast, Lucas and Luna explore the emerging world of wearable microneedle patches that deliver drugs through the skin without pain. They focus on the specific case of Zosano Pharma's transdermal patch for migraine, which failed in clinical trials in 2021, and contrast it with newer players like Vaxxas and LTS Lohmann that are targeting vaccines and insulin. Lucas breaks down the key engineering challenge: how to make microneedles long enough to penetrate the stratum corneum but short enough to avoid pain receptors. Luna asks whether the FDA's regulatory pathway for combination products is slowing adoption. The hosts also discuss the potential market size: Grand View Research estimates the transdermal drug delivery market could reach $12.3 billion by 2027. They debate whether the biggest win will be in chronic disease management (insulin, GLP-1 agonists) or mass vaccination campaigns. The episode ties the conversation to listener support, noting that independent digital health journalism helps separate real innovation from hype. A focused, technical conversation for anyone interested in how wearables are moving beyond sensors into therapeutics. #DigitalHealth #WearableTech #MicroneedlePatches #DrugDelivery #Transdermal #ZosanoPharma #Vaxxas #LTSLohmann #Migraine #Insulin #GLP1 #FDA #CombinationProducts #Business #Technology #FexingoBusiness #BusinessPodcast #HealthTech Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    11 分
  • How Digital Health Startups Are Redesigning the Doctor Visit
    2026/06/07
    Lucas and Luna explore how a handful of digital health startups are rethinking the primary care visit from the ground up. The episode focuses on 'ambient listening' AI — software that listens to the patient-clinician conversation and automatically generates clinical notes, diagnoses, and billing codes in real time. They examine the specific case of Abridge, which recently partnered with several major health systems, and discuss the numbers: how much time physicians actually spend on documentation (around 15 minutes per appointment after hours), and how ambient listening aims to cut that to zero. They also touch on the tricky regulatory question — when an AI listens in, who owns the transcript? And what happens when the model makes a clinical error in its note? The hosts treat the topic with a sharp business lens, comparing the unit economics of ambient listening to traditional medical scribes (human scribes cost roughly $15 to $20 per hour; AI scribes are targeting $1 to $2 per visit). The episode closes with a forward-looking question: if the listening is automated, and the note-taking is automated, what part of the doctor-patient relationship becomes the truly human middle? #AmbientListening #AIinHealthcare #PrimaryCare #DigitalHealth #Abridge #MedicalScribes #ClinicianBurnout #HealthTech #Business #FexingoBusiness #BusinessPodcast #DoctorPatient #EHR #Documentation #HealthAI #Startup #Podcast #Technology Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    10 分
  • How MedTech Startups Are Navigating the FDA's Software Pathway
    2026/06/06
    In episode 35 of The Digital Health Podcast, Lucas and Luna unpack the FDA's evolving framework for regulating software-as-a-medical-device (SaMD). They focus on the agency's 2025 guidance on AI/ML-enabled devices and how it affects startups like IDx and Caption Health. Lucas explains the 'predetermined change control plan'—a mechanism that lets algorithms update without full re-clearance. Luna questions whether this really accelerates innovation or just shifts risk. They also discuss the de novo pathway, the 510(k) exemption for low-risk tools, and why some digital health companies are choosing not to pursue FDA clearance at all. A concrete look at regulatory strategy for anyone building or investing in health software. #DigitalHealth #SaMD #FDA #SoftwareAsAMedicalDevice #AIinHealthcare #MedTech #RegulatoryStrategy #IDx #CaptionHealth #PredeterminedChangeControlPlan #510kClearance #DeNovoPathway #Business #Technology #HealthTech #FexingoBusiness #BusinessPodcast #DigitalTherapeutics Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    9 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません